biointron_3

Over four years have passed since the first SARS-CoV-2 outbreak, and scientific advancements have reshaped our understanding of immunity and virus dynamics.

Taking place from September 30 to October 3, 2024, Discovery on Target 2024 is renowned for its comprehensive program, featuring keynote presentations, breakout sessions, and interactive panel discussions. The conference covers a wide range of topics, including target identification and validation, hit-to-lead optimization, and novel therapeutic modalities. It offers attendees the opportunity to stay at the forefront of the drug discovery field and to engage in meaningful discussions with peers and experts.

We are excited to announce that Biointron will be attending BIO Japan 2024, set to take place from October 9 to 11, 2024, in Yokohama, Japan. As Asia's largest event for the biotechnology industry, BIO Japan brings together industry leaders, researchers, and professionals to explore the latest advancements and innovations in biotechnology.

We are delighted to announce that Biointron will be participating in the Biologics USA 2024 conference, taking place from October 3 to 4, 2024, in San Diego, California. This event is a premier gathering for the biologics sector, providing a unique platform for industry leaders, researchers, and professionals to discuss the latest advancements and trends in biologics.

We are delighted to announce that Biointron will be participating in the 15th Annual World Bispecific Summit, scheduled to take place from September 3 to 5, 2024, in Boston, Massachusetts. This summit is a cornerstone event for the bispecific antibody community, attracting thought leaders and industry experts worldwide to discuss the latest innovations and breakthroughs in bispecific therapeutics.

We are excited to announce that Biointron will be participating in the upcoming BIO Asia - Taiwan Conference, set to take place from July 24 to 28, 2024, at the Taipei Nangang Exhibition Center. This prestigious event is a major gathering for the biotechnology and pharmaceutical industries, attracting professionals and companies from around the globe.

We are pleased to announce that Biointron will be attending the Next-gen Immuno-Oncology Conference 2024, scheduled for June 20-21, 2024, in Boston, Massachusetts. This distinguished event, organized by MarketsandMarkets, brings together leading experts, researchers, and industry professionals to discuss the latest advancements and trends in immuno-oncology.

Ozempic, a brand name for the drug semaglutide, was originally developed to manage type 2 diabetes by improving blood sugar control. As a GLP-1 receptor agonist, it mimics a hormone that regulates glucose metabolism and appetite. Beyond its success in diabetes treatment, Ozempic has garnered signifi

We are delighted to announce that Biointron will be attending the Antibody Therapeutics Xchange 2024 Boston, which will take place on June 17, 2024. This exclusive event is a gathering of the leading minds in antibody therapeutics, offering a unique platform for collaboration, innovation, and knowledge sharing.

Antibody drugs for diabetes typically target specific molecules involved in the regulation of blood sugar levels or the immune response against insulin-producing cells, or specific hormones or receptors involved in glucose metabolism. For instance, teplizumab (Tzield), targets CD3 on T cells, thus deactivating immune cells which attack β-cells.

This month heralded the release of groundbreaking news involving the monoclonal antibody tegoprubart, which facilitated the successful transplantation of a genetically edited pig kidney into a 62-year-old man grappling with end-stage kidney disease.

In March 2024, Cyagen and Biointron officially signed off on their strategic partnership, forging an alliance in antibody drug development. This partnership aims to fully leverage the strengths of Cyagen's HUGO-Ab™ fully humanized mouse antibody discovery platform and Biointron&#

In the realm of combating bacterial infections and antimicrobial resistance, antibodies are beginning to stand out as a therapy with innovative strategies and engineering methods continually being published. This month’s trend will focus on the developments in ‘antibiotic antibodies’, antibody-antibiotic conjugates, and antibody antimicrobials, which are particularly important for immunocompromised patients.

Entering into the new year, the popularity of antibody-drug conjugates (ADCs) in the biopharma industry shows no signs of slowing down. In 2023, there were a record number of licensing partnerships in the ADC space, particularly Merck’s $22 billion deal with Daiichi Sankyo, Inc.

We are thrilled to announce Biointron's participation in the 20th Annual PEGS Boston (The Protein Engineering Summit), happening from May 13-17, 2024, in Boston, MA. Organized by CHI, this summit is the epitome of innovation in protein and antibody engineering, a field where Biointron has continually demonstrated its leadership.